Related posts

Consumer, housing data misses, stocks sinkWall Street edges up, Tesla beats3 Best U.S. Healthcare ETFs
Investor Insights

This summary was created by AI, based on 13 opinions in the last 12 months.

Experts are generally positive about Stryker Corp. (SYK-N), highlighting its strong position in the medical device market, its loyal customer base, and international growth opportunities. They also note the impact of the Covid-19 pandemic on the company's business and the potential for future acquisitions. While there are concerns about the stock's valuation and recent downtrend in the chart, overall confidence in the company's long-term prospects remains high.

Consensus
Positive
Valuation
Fair Value
PAST TOP PICK
Stryker Corp.
(A Top Pick Nov 20/23, Up 35%)

Such an important area. Fell during Covid because classified as "elective" surgeries, but they aren't, as they help maintain quality of life without medication. Lots of opportunity to grow in EMs. Lots of free cashflow, which can be used for acquisitions.

biotechnology / pharmaceutical
HOLD
Stryker Corp.

Good products, good reputation. Good long-term investment in the medical device area. If you own it, keep holding. Her exposure to the space is via ABT and JNJ.

(Analysts’ price target is $379.00)
biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick Sep 11/23, Up 21%)

73% of their business comes from the U.S. with the rest from Europe and emerging markets. They make great surgical products (i.e. hip replacements). Also, surgeons are loyal to SYK products and rarely change brand. Aging demographics and foreign markets offer growth.

biotechnology / pharmaceutical
WAIT
Stryker Corp.

Problem with the chart right now is it's making a lower high and a lower low. Looks like we just took out the last low. In the near term, that's a downtrend. He doesn't buy into downtrends or ride downhill rollercoasters. If it does decide to stop, reasonable chance that it will stop near old breakout point, ~$300. If it finds support and bounces off, could be a great time to buy.

biotechnology / pharmaceutical
BUY
Stryker Corp.

Wonderful business, one of the best operators in healthcare. Balance sheet back to being clean and ready to make acquisitions. Expects extremely strong results. A leader, and gaining market share. Valuation is pricey, needs to deliver future gains, so stock's hit a wall. He's still buying, loves it long term.

(Analysts’ price target is $372.00)
biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick Jun 21/23, Up 19%)

Sales machine. Market leader in joint replacement and medical products. Post-pandemic backlogs still huge. Double-digit topline revenue growth last few years, should continue. Acquisitive. Good free cashflow. Still growth in EMs. Valuation's run up, but he's not selling.

biotechnology / pharmaceutical
PAST TOP PICK
Stryker Corp.
(A Top Pick May 12/23, Up 15%)

Has since sold shares. Believes stock is fully valued. Medical device business performing well. Surgeries recovered after pause during Covid-19 pandemic. 

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Demographic tailwind. User loyalty. Most revenue comes from US. Global growth opportunities, especially in EM. Medical devices are really changing how people live. Covid backlog is being caught up. Tuck-on acquisitions. Yield is 0.9%.

(Analysts’ price target is $360.04)
biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Revenue: US (73%), developed world (19%), emerging markets (rest). Lots of good growth internationally. Demographic play. Strong brand loyalty. Free cash will be used for acquisitions. Great compounding story for the next several years. Yield is 0.9%.

(Analysts’ price target is $356.78)
biotechnology / pharmaceutical
COMMENT
Stryker Corp.

AI and weight-loss drugs are the two manias in the market now. SYK makes medical devices (hip and knee), but you must be below a certain weight to qualify for these operations.  The weight-loss drugs will open a greater market for SYK.

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Great story. Medical devices is a really important area of healthcare. Tremendous brand loyalty from end-user, plus a demographic play. Great operating margins and quarterly numbers, which will just keep on getting better. Lots of growth internationally. Yield is 0.9%.

(Analysts’ price target is $350.67)
biotechnology / pharmaceutical
BUY
Stryker Corp.

Medical devices are an important area that keeps people out of expensive hospitals, improves quality of life, and reduces reliance on drugs. Great advances, which will grow over the years. You want to be in this area. He owns SYK and JNJ in the space.

biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Medical devices. Joint replacements. Huge backlog due to Covid. Costs increased from supply chains and labour, but now sorted out. Really improves quality of life. Great business, lots of growth from aging demographics. Lots of growth internationally, too. Once a doctor "buys in", tremendous brand loyalty. Yield is 1%.

(Analysts’ price target is $318.71)
biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

It is in the medical devices field producing parts for artificial knees, hips, etc. and improving patient quality of life. Surgeons tend to stick with the same products so there is a stability to its income. The backlog from Covid is being decreased but there is room to grow internationally and an aging population needs more of these surgeries. 72% of its business comes from the U.S. and the rest from emerging markets and the developed world. They have lots of free cash flow to buy other companies.       Buy 18  Hold 11  Sell 1

(Analysts’ price target is $314.49)
biotechnology / pharmaceutical
TOP PICK
Stryker Corp.

Doing well given the backlog in surgeries. 73% of their business is in the US, but there's growth in emerging markets where they also operate. Doctors stick with their products and seldom change. Also, aging demographics help. They could make acquisitions, which will benefit them.

(Analysts’ price target is $311.03)
biotechnology / pharmaceutical
Showing 1 to 15 of 157 entries

Stryker Corp.(SYK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 7 stock analysts published opinions about SYK-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

7 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2024-12-13, Stryker Corp. (SYK-N) stock closed at a price of $374.68.